In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

DARA BioSciences, Inc.

http://www.darabio.com/

Latest From DARA BioSciences, Inc.

Midatech Survival Plan Scuppered By Shareholders

The UK firm's shareholders have not approved plans to acquire Bioasis, a decision that puts Midatech in a tricky situation as its cash will run out by mid-March.

M & A Business Strategies

Midatech Bets on Bioasis Merger For Survival

With just enough cash to stay afloat until the first quarter, Midatech is linking up with US-based, Canada-listed Bioasis to create a new rare disease player, Biodexa.

M & A Rare Diseases

Elypta Drops Data Showing Power Of Metabolite-Based MCED Test

Elypta’s MIRAM kit for multi-cancer early detection performed well in a large-scale study.

Cancer Diagnostics

Shionogi Reveals Strategy For COVID-19 Drug Xocova

Shionogi is hoping to demonstrate the efficacy of its oral COVID-19 candidate Xocova through an appropriate primary endpoint in its Phase III trial, while the Japanese firm is also eyeing global expansion for the drug should a world-first domestic approval be granted.

Coronavirus COVID-19 Research & Development
See All

Company Information

  • Other Names / Subsidiaries
    • Oncogenerix, Inc.
    • Point Therapeutics, Inc.
UsernamePublicRestriction

Register